Breaking News: Expert Perspective on Venclexta (venetoclax) Approval The U.S. Food and Drug Administration (FDA) has approved a new drug Venclexta (venetoclax) for use in CLL patients with the 17p deletion. Andrew Schorr interviewed CLL expert Dr. Thomas Kipps to get his perspective on what this new approval means for patients. Get email alerts | Subscribe on YouTube | Like on Facebook | Follow on Twitter | Follow on Google+ |